GTBP
GT Biopharma, Inc.0.7200
+0.0929+14.8%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.66MP/E (TTM)
-Basic EPS (TTM)
-3.50Dividend Yield
0%Recent Filings
10-K
FY2025 results
GT Biopharma posted a $28.4M net loss for FY2025 ended December 31, 2025, up from $13.2M in 2024, driven by $28.7M non-cash hit from Greenshoe Rights liability recognition offset by $11.4M fair value gain; R&D fell 40% to $3.5M as production costs eased post GTB-3650 IND clearance in June 2024 with enrollment starting January 2025. Cash burn held steady at $12.9M while ending $6.9M cash supports runway into mid-2026 amid $20M committed equity facility. Q4 momentum showed clinical progress with GTB-5550 IND cleared January 2026 for mid-year start. Yet going concern doubts loom without fresh capital.
8-K
Restates Q2/Q3 2025 financials
GT Biopharma disclosed on March 1, 2026, that its Q2 and Q3 2025 10-Qs can't be relied upon due to misclassifying $28.7M Greenshoe Rights as equity instead of a liability under ASC 480. Restatements flip Q2 to a $30.2M net loss from $1.5M, while Q3 swings to $4.1M loss attributable to common after $11.4M fair value gain. Cash flows unchanged. Big restatement hit.
8-K
Nasdaq bid price deficiency notice
GT Biopharma received a Nasdaq notice on November 20, 2025, for failing the $1 minimum bid price rule after 30 consecutive business days below it. Shares continue trading as GTBP with 180 days until May 19, 2026, to hit $1 for 10 straight days. No delisting yet. Company eyes options like a reverse split but offers no guarantees.
8-K
Q3 loss narrows; trials advance
GT Biopharma reported Q3 2025 net loss of $3.1 million, down from $3.4 million last year, driven by R&D expenses dropping to $0.6 million from $1.3 million amid lower production costs. Cash stands at $2.6 million, funding operations into Q1 2026. GTB-3650 Phase 1 trial advanced to Cohort 4; GTB-5550 IND submission eyed for late December 2025 or January 2026. Runway burns fast.
10-Q
Q3 FY2025 results
GT Biopharma narrowed its Q3 operating loss to $3.4M from $3.6M y/y (derived), while nine-month net loss improved to $5.3M from $9.4M y/y, driven by 51% lower R&D at $634K and hefty cuts in legal fees. Cash burn eased to $8.9M YTD versus $10.4M prior, funded by $7.5M from Series L preferred raises; quarter-end cash sits at $2.5M with $3M positive working capital after mezzanine reclass. R&D centers on GTB-3650 enrollment and GTB-5550 GMP. Cash won't last without more financing.
FATE
Fate Therapeutics, Inc.
1.09-0.03
GBIO
Generation Bio Co.
5.38-0.01
GRI
GRI Bio, Inc.
0.48+0.00
HOOK
HOOKIPA Pharma Inc.
0.87-0.02
INAB
IN8bio, Inc.
1.50-0.10
KAPA
Kairos Pharma, Ltd.
0.74+0.00
KROS
Keros Therapeutics, Inc.
21.53+0.30
KZR
Kezar Life Sciences, Inc.
6.30+0.02
MRKR
Marker Therapeutics, Inc.
1.27-0.12
TCBPY
TC BioPharm (Holdings) plc
0.11+0.00